CoChat

Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial

Open access
Leventogiannis, Konstantinos, Kyriazopoulou, Evdoxia, Antonakos, Nikolaos, Kotsaki, Antigone, Tsangaris, Iraklis, Markopoulou, Dimitra, Grondman, Inge, Rovina, Nikoleta, Theodorou, Vassiliki, Antoniadou, Eleni, Koutsodimitropoulos, Ioannis, Dalekos, George, Vlachogianni, Glykeria, Akinosoglou, Karolina, Koulouras, Vassileios, Komnos, Apostolos, Kontopoulou, Theano, Prekates, Athanassios, Koutsoukou, Antonia, van der Meer, Jos W.M., Dimopoulos, George, Kyprianou, Miltiades, Netea, Mihai G., Giamarellos-Bourboulis, Evangelos J. · 2022 · Cell Reports Medicine
Cited by 150

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The state of immune activation may guide targeted immunotherapy in sepsis. In a double-blind, double-dummy randomized clinical study, 240 patients with sepsis due to lung infection, bacteremia, or acute cholangitis were subjected to measurements of serum ferritin and HLA-DR/CD14. Patients with macrophage activation-like syndrome (MALS) or immunoparalysis were randomized to treatment with anakinra or recombinant interferon-gamma or placebo. Twenty-eight-day mortality was the primary endpoint; sepsis immune classification was the secondary endpoint. Using ferritin >4,420 ng/mL and <5,000 HLA-DR receptors/monocytes as biomarkers, patients were classified into MALS (20.0%), immunoparalysis (42.9%), and intermediate (37.1%). Mortality was 79.1%, 66.9%, and 41.6%, respectively. Survival after 7 days with SOFA score decrease was achieved in 42.9% of patients of the immunotherapy arm and 10.0% of the placebo arm (p = 0.042). Three independent immune classification strata are recognized in sepsis. MALS and immunoparalysis are proposed as stratification for personalized adjuvant immunotherapy. Clinicaltrials.gov registration NCT03332225.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2022.100817

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 150

Metadata

Authors
Leventogiannis, K., Kyriazopoulou, E., Antonakos, N., Kotsaki, A., Tsangaris, I., Markopoulou, D., Grondman, I., Rovina, N., Theodorou, V., Antoniadou, E., Koutsodimitropoulos, I., Dalekos, G., Vlachogianni, G., Akinosoglou, K., Koulouras, V., Komnos, A., Kontopoulou, T., Prekates, A., Koutsoukou, A., van der Meer, J. W. M., Dimopoulos, G., Kyprianou, M., Netea, M. G., & Giamarellos-Bourboulis, E. J.
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2022-11
Volume
3
Issue
11
Pages
100817
ISSN
2666-3791 (ISSN-L)
OpenAlex
W4309333178
Cited by
150
References
5
FWCI
14.85
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial. https://app.cochat.ai/papers/10.1016/j.xcrm.2022.100817
The paper
Leventogiannis, K., Kyriazopoulou, E., Antonakos, N., Kotsaki, A., Tsangaris, I., Markopoulou, D., Grondman, I., Rovina, N., Theodorou, V., Antoniadou, E., Koutsodimitropoulos, I., Dalekos, G., Vlachogianni, G., Akinosoglou, K., Koulouras, V., Komnos, A., Kontopoulou, T., Prekates, A., Koutsoukou, A., . . . Giamarellos-Bourboulis, E. J. (2022). Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2022.100817

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.